Neurodegenerative disease

Researchers are following 64 people with cerebral adrenoleukodystrophy (CALD) for 15 years after they received a one-time gene therapy called eli-cel in earlier studies. The therapy uses the patient's own stem cells, modified to carry a working copy of the gene that is faulty in …

Researchers test GCB-001, a gene therapy given as a single injection into the spinal fluid, in children aged 2 to 12 with type 2 spinal muscular atrophy who can sit alone but cannot walk. The trial checks safety and whether the treatment improves motor skills over 12 months. It i…

This trial tests a new vaccine called LBVD, which combines protection against six diseases: diphtheria, tetanus, whooping cough, hepatitis B, polio, and Hib. The study enrolls healthy infants around 6 to 8 weeks old who receive three doses at 6, 10, and 14 weeks of age. Researche…

This trial is testing an experimental vaccine made from virus-like particles (VLPs) that mimic polio viruses without causing disease. It aims to see if this vaccine is safe and triggers a strong immune response in healthy infants starting at 6 weeks old and toddlers aged 12-18 mo…

This study is a long-term extension of earlier trials testing the drug riliprubart in adults with CIDP, a condition where the immune system attacks the nerves, causing weakness and numbness. About 300 participants who completed a prior riliprubart study will continue receiving th…

This early-stage trial tests a drug called NIO752 in 38 people with mild Alzheimer's or mild cognitive impairment due to Alzheimer's. The drug is given as one or two injections into the spinal fluid to see if it can lower levels of tau protein, a key marker of Alzheimer's damage.…

Researchers are testing whether transcranial static magnetic field stimulation (tSMS), delivered via a helmet worn at home, can slow the progression of amyotrophic lateral sclerosis (ALS). About 60 adults with recent-onset ALS will use the device for two daily sessions of 120 min…

This study tests whether benfotiamine, a form of vitamin B1, can safely slow memory and thinking decline in people with early Alzheimer's. About 406 adults aged 50-89 with mild symptoms will take the drug or a placebo for up to 72 weeks. Researchers will measure changes in cognit…

This phase 3 trial compares two drugs for primary progressive multiple sclerosis (PPMS), a form of MS that steadily worsens. About 985 adults with PPMS will receive either daily oral fenebrutinib or intravenous ocrelizumab (plus matching placebos) to see which better delays disab…

This study tests a new medicine called PYC-001, given as an injection into the eye, for people with a genetic condition that damages the optic nerve (OPA1 optic atrophy). The main goal is to check if the treatment is safe and tolerable. About 18 adults will receive a single dose,…

This Phase 3 study compares fenebrutinib, an experimental oral drug, to teriflunomide, an approved MS therapy, in 751 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays disability progression. Participants take eit…

This early-stage trial tests an experimental drug called BI 3000202 in 16 adults with rare type 1 interferonopathies, such as Aicardi-Goutières syndrome. Participants take a low dose for 4 weeks, then a higher dose for 36 weeks. The main goal is to see if the drug is safe and how…

This early-stage study is testing a new drug called RO7121932 in 129 people with multiple sclerosis (MS). The goal is to check if the drug is safe and how the body handles it when given as a single or multiple doses, either through a vein or under the skin. Participants are not o…

This study tests an experimental drug called RO7126209 (Trontinemab) in people with early to moderate Alzheimer's disease. The drug is given by IV infusion and aims to reduce amyloid plaques in the brain, a hallmark of Alzheimer's. About 241 participants will receive either the d…

This study tests the safety and dosing of ocrelizumab in 23 children and teens (ages 10–18) with relapsing-remitting multiple sclerosis over 2 years. The goal is to find the best dose for a future larger study. Participants receive the drug and are monitored for side effects and …

Researchers are testing an experimental compound called HK-001 in healthy volunteers to find the highest dose people can take without serious side effects. The trial also measures how the body absorbs and processes the drug. Participants receive either HK-001 or a placebo, first …

This study follows 403 adults and children with spinal muscular atrophy who are already taking risdiplam (Evrysdi) as prescribed by their doctor. Researchers will track side effects and how well the drug works over about two years. The goal is to see if risdiplam remains safe and…

This study tests whether adding an experimental drug (RO7204239) to an existing SMA medicine (risdiplam) can help people with spinal muscular atrophy build stronger muscles and move better. The trial includes about 259 children and young adults, ages 2 to 25, who can walk. Resear…

This early-stage study tests a new drug called RO7812653 in 50 people with early Alzheimer's disease. The main goal is to check if the drug is safe and how the body handles it. Participants receive a single dose injected into the spine and are closely monitored for side effects.

This phase 3 trial compares a new drug, BMS-986365, against standard treatments (docetaxel or other hormone therapies) in 960 men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The main goal is to see if the new drug delays ca…

This study tests a vaccine called AADvac1, which targets tau tangles in the brain, a hallmark of Alzheimer's. It will be given alone or with another drug (donanemab) to 450 adults aged 50-80 with very early Alzheimer's. The goal is to see if this approach can reduce tau buildup a…

This UK trial tests whether cladribine tablets, taken for just 8-10 days a year over two years, can slow the loss of hand function in people with advanced multiple sclerosis (MS). The study includes 204 participants with significant disability (EDSS 6.5-8.5). Half receive cladrib…

This study tests a device called a motor neuroprosthesis, an implantable brain computer interface designed to help people with severe paralysis control digital devices like computers or tablets. The device aims to bypass damaged motor pathways and transmit brain signals directly …

This early-phase trial tests a single dose of YTB323, a CAR-T cell therapy, in 28 adults with non-active progressive multiple sclerosis. The study aims to check safety and track disability changes over time. Participants must be 18–60 and able to undergo lumbar punctures and MRIs…

This phase 3 trial tests whether satralizumab can prevent relapses in people with MOGAD, a rare disease where the immune system attacks the brain and spinal cord. About 152 participants aged 12 and older will receive either the drug or a placebo. The main goal is to see if satral…

This Phase 3 trial tests whether an experimental oral drug, KPS-0373, can improve movement and coordination in people with spinocerebellar degeneration, a condition that causes progressive clumsiness and balance problems. About 142 Japanese adults with mild to moderate ataxia wil…

This study tests omaveloxolone, a drug already approved for adults with Friedreich's ataxia, in children aged 2 to 15. Researchers want to see how the drug moves through children's bodies and whether it is safe. The study involves two parts: a single dose followed by daily dosing…

This Phase 2 trial tests whether a combination of over-the-counter antioxidants, including vitamin E and N-acetylcysteine, can slow the progression of amyotrophic lateral sclerosis (ALS). Researchers will give high doses of these supplements to 21 adults with ALS and measure chan…

This early-phase study tests an experimental cell therapy called YTB323 in about 28 people with relapsing multiple sclerosis whose disease is still active despite taking strong medications. The goal is to see if YTB323 is safe and can control the disease. Participants receive a s…

This early-stage study tests a new drug called RG6496 in people who carry the gene for Huntington's disease. The main goal is to check if the drug is safe and how the body handles it. About 40 participants will receive a single dose injected into the spine, with some getting a pl…

This trial compares two treatment strategies for people with relapsing-remitting multiple sclerosis: starting with high-efficacy drugs early versus starting with standard first-line therapies and switching if needed. The study involves 900 participants across multiple sites and t…

This study looks at whether people with early relapsing multiple sclerosis (MS) can stop taking ocrelizumab (Ocrevus) after two years without their disease coming back. All 123 participants will receive ocrelizumab for the first two years. Then, some will switch to a placebo whil…

This study tests whether deep brain stimulation (DBS) can improve thinking and memory in people with early Alzheimer's disease. Two participants will have electrodes implanted in a brain area that produces a key chemical for memory. The goal is to see if daily, one-hour stimulati…

This trial tests whether a dietary supplement called NVP-NK4146 can improve memory and thinking in older adults with mild cognitive impairment due to Alzheimer's disease. Participants aged 60 and older will take the supplement or a placebo twice daily for 36 weeks. Researchers wi…

This trial tests the long-term safety and effectiveness of apitegromab, an investigational antibody that blocks myostatin, a protein that limits muscle growth. People with type 2 or type 3 spinal muscular atrophy who completed earlier apitegromab studies can join. Researchers wil…

This trial asks whether starting with highly effective MS drugs right away is better than starting with milder drugs and switching to stronger ones only if needed. Researchers will follow about 800 adults with relapsing-remitting MS for several years, using MRI scans and disabili…

This study tests a new medicine called ONO-2020 in 240 people with mild to moderate Alzheimer's disease. The goal is to see if it can safely improve memory and thinking skills. Participants will receive either the drug or a placebo for 26 weeks, and researchers will track side ef…

This phase 3 trial tests whether people with active multiple sclerosis who have been stable on Ocrevus for at least two years can safely switch to annual infusions instead of the standard every-6-month schedule. The goal is to see if the less frequent dosing is just as good at pr…

This phase 2 study tests a vaccine called JNJ-64042056 in 55 people with very early signs of Alzheimer's (no symptoms yet but tau buildup in the brain). The vaccine is designed to train the immune system to attack tau protein, which forms tangles in Alzheimer's. Participants rece…

This study tests an investigational drug called rozanolixizumab in adults with MOG antibody-associated disease (MOGAD), a rare condition where the immune system attacks the brain and spinal cord. The main goal is to see if the drug can prevent or delay relapses (flare-ups) compar…

This trial tests whether an experimental drug called donanemab can slow the mental and functional decline seen in early Alzheimer's disease. Participants with mild symptoms receive either donanemab or a placebo via IV infusion, and researchers track changes in cognition and daily…

This phase 2 trial tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can improve outcomes for men with castration-resistant metastatic prostate cancer. About 60 participants will receive either one or two DNA vaccines along with pembrolizumab f…

This study is a long-term follow-up for people with relapsing multiple sclerosis who previously completed a ublituximab trial. It aims to see if the drug remains safe and effective over time. About 1100 participants will receive ublituximab infusions, and researchers will track r…

This phase 3 trial tests whether a shot (subcutaneous) of ublituximab works as well as the standard IV infusion for people with relapsing multiple sclerosis. About 360 participants are enrolled. The main goal is to compare drug levels in the blood over 24 weeks, along with safety…

This trial tests whether delivering interdisciplinary care via video telehealth can improve access and satisfaction for people with Lewy body dementia (LBD) and their caregivers. Participants receive remote consultations with a team of specialists, including a neurologist, therap…

This early-stage trial tests the safety and tolerability of a new drug called VX-670 in 52 adults with myotonic dystrophy type 1 (DM1), a genetic condition that causes muscle weakness and other problems. Participants receive either VX-670 or a placebo, and researchers will monito…

This study tests whether a daily soy-based supplement called Equol can slow down stiffening of the arteries, small blood vessel damage in the brain, and memory decline. About 369 older adults (ages 65-85) will take Equol or a placebo for two years. Researchers will measure artery…

This Phase 2 trial tests fenebrutinib, an oral drug, in 109 people with relapsing multiple sclerosis. Participants receive either the drug or a placebo for 12 weeks, and researchers measure new brain lesions on MRI scans. The goal is to see if fenebrutinib can reduce disease acti…

This phase 3 trial tests whether PLX-200 (gemfibrozil) can safely slow the progression of CLN3 disease, a rare genetic disorder that causes loss of motor skills, vision, and seizures in children. About 39 kids aged 6-18 will receive either the drug or a placebo for up to 96 weeks…

This program offers the drug ibudilast (MN-166) to people with ALS who cannot join other clinical trials. Participants take the drug by mouth, starting at a lower dose and increasing. The goal is to see if ibudilast can slow the progression of ALS. The program also collects blood…

This study tests the long-term safety of the drug tolebrutinib in 2,500 adults with relapsing or progressive multiple sclerosis. Participants previously took part in earlier trials and will continue taking tolebrutinib or a placebo for up to several years. The goal is to see if t…

This phase 3 trial tests whether rituximab, a cheaper drug, works as well as ocrelizumab for active multiple sclerosis. About 600 adults with relapsing or progressive MS will receive one of the two drugs. The main goal is to see if rituximab can prevent new brain lesions as effec…

This study checks the long-term safety of tofersen (Qalsody) in 12 Chinese adults with a specific genetic form of ALS (SOD1-ALS). Participants receive 13 doses of the drug injected into the spine over about a year. The main goal is to track any side effects and how the drug moves…

This study compares two daily pills—fenebrutinib and teriflunomide—in about 746 adults with relapsing multiple sclerosis. The goal is to see which one better reduces relapses and delays worsening disability. Participants take one of the two drugs for several years, with an option…

This early-stage trial is testing a new way to give ocrelizumab (Ocrevus) for multiple sclerosis — as a simple shot under the skin instead of a long IV infusion. About 75 adults with MS will receive increasing doses to see if the new form is safe and tolerable. If it works, it co…

This study tests whether people with relapsing-remitting multiple sclerosis (MS) who have been stable on anti-CD20 therapies can safely switch to a fumarate drug like Tecfidera or Vumerity. The goal is to see if the switch keeps the disease inactive—meaning no relapses, no new br…

This study tests whether two HIV medications, emtricitabine and Descovy, are safe for people with mild cognitive impairment (MCI), a condition that can lead to Alzheimer's. Researchers think these drugs might slow disease progression by blocking a process linked to Alzheimer's. A…

This study tests the long-term safety and effectiveness of an experimental drug called VX-670 in adults with myotonic dystrophy type 1 (DM1). Participants who completed a previous VX-670 study can join. The drug is given through a vein, and researchers will monitor side effects a…

This study tests a new maintenance dosing schedule for ofatumumab, a drug used to control relapsing multiple sclerosis (MS). Researchers want to see if the new schedule is as safe and effective as the current approved dose. About 196 adults with relapsing MS will take part, and t…

This study tests a drug called riliprubart in 140 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hasn't improved with standard care. Participants receive either riliprubart or a placebo for up to 111 weeks. The main goal is to see if the drug reduces di…

This study compares two versions of the drug ocrelizumab given as a shot under the skin in people with multiple sclerosis. The goal is to see if the new test version works the same as the current one. About 182 participants with relapsing or primary progressive MS will take part.

This trial tests whether a 12-month aerobic walking program can improve cognitive processing speed and brain connectivity in adults with multiple sclerosis who have slowed thinking. Participants will be randomly assigned to one of two home-based walking programs that differ in in…

This trial tests an experimental drug called NPI-001 in people aged 50 to 85 with mild cognitive impairment or mild Alzheimer's disease. Participants take either the drug or a placebo as tablets twice daily for 12 months, with doses increasing over time. The study measures safety…

This study tests the long-term safety of an experimental drug called UCB0107 (bepranemab) in people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and balance. Participants who completed a prior study receive regular infusions of the drug. …

This trial tests a personalized drug called nL-TARDB-006, designed for people with ALS caused by a specific genetic mutation in the TARDBP gene. The drug is an antisense oligonucleotide, which aims to target the genetic cause of the disease. Six participants will receive the trea…

This study tests whether a higher dose of the drug ocrelizumab can better control relapsing multiple sclerosis (MS) and delay disability compared to the standard dose. About 864 adults with relapsing MS will receive either the higher or standard dose every 24 weeks. The main goal…

This study follows about 1,300 people with multiple sclerosis who are already taking ocrelizumab to see how safe and effective it is over many years. Participants continue their usual treatment, and researchers track side effects, disability changes, and brain scans. The goal is …

This Phase 3 study tests whether the drug leriglitazone can help adult men with cerebral adrenoleukodystrophy (cALD), a rare and serious brain disease. The main goal is to see if the drug delays death or the need for permanent breathing support compared to a placebo. About 40 men…

This trial tests whether robot-assisted neurorehabilitation can improve coordination, balance, and walking in adults with ataxia, a condition that affects movement control. Participants will receive either robotic or standard rehabilitation, and researchers will measure changes i…

This Phase 1 study tests the safety of OLX-07010, a drug designed to stop tau proteins from clumping in the brain—a hallmark of Alzheimer's disease. Researchers will give single or multiple doses to 88 healthy adults and elderly volunteers to see how the body handles the drug and…

This study tracks the safety and effectiveness of Spinraza (nusinersen) in people with spinal muscular atrophy (SMA) who receive the drug as part of routine care in Korea. Researchers will monitor for side effects and measure changes in motor skills over time. The goal is to see …

This study tests lecanemab, an antibody that targets amyloid plaques in the brain, in 40 people who carry a gene mutation that causes early-onset Alzheimer's. Participants previously received another anti-amyloid drug and will now receive lecanemab to see if it can fully clear am…

This study tests whether two drugs, E2814 and lecanemab, can slow the progression of Alzheimer's in people who carry a gene mutation that causes the disease. About 197 participants will receive either the drugs or a placebo over 2 to 4 years. Researchers will measure changes in t…

This study tests whether experimental drugs can slow down memory and thinking problems in people who have a gene mutation that causes Alzheimer's disease. About 490 adults aged 18-80 with this genetic risk are taking either a study drug or a placebo. The goal is to see if the dru…

This Phase 3 trial is testing whether a higher dose of the drug ocrelizumab (Ocrevus) can better slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 769 adults with PPMS are receiving either the standard approved dose or a higher dose b…

This study tests a drug called ACP-204 for treating psychosis (hallucinations or delusions) in people with Lewy body dementia. It is a 52-week open-label extension, meaning all 126 participants will receive the drug. The main goal is to check for side effects over the long term. …

This study tests an oral drug called SKY-0515 in 500 adults with Huntington's disease who have already completed a prior study of the same drug. The goal is to see if the drug can safely lower harmful proteins and improve symptoms over the long term. Participants must be 25 or ol…

This study is testing the drug ocrelizumab in 927 people with progressive multiple sclerosis (MS), a form of the disease that steadily worsens. Participants receive infusions every 24 weeks for about 4 years. The main goal is to see if the drug can stop or slow disability progres…

This phase 2 trial tests whether low-dose interleukin-2 (IL-2), an immune-modulating drug, can slow cognitive decline in people with early Alzheimer's disease. Forty participants will receive either IL-2 injections or a placebo for several months, and their cognitive function wil…

This trial investigates the long-term safety of ecopipam, a drug that blocks dopamine D1 and D5 receptors, in children, adolescents, and adults with Tourette syndrome. Participants who completed a prior study may enroll and receive ecopipam for up to 24 weeks or longer. The main …

This study tests whether a daily 10 mg pill called Xanamem can safely slow memory and function loss in people with mild or moderate Alzheimer's dementia. About 247 participants will receive either Xanamem or a placebo for 36 weeks, with an option to continue the drug for up to 10…

This study investigates whether intensively lowering systolic blood pressure with FDA-approved medications can reduce the buildup of amyloid and tau proteins in the brain—hallmarks of Alzheimer's disease. The trial enrolls adults aged 60-85 with high blood pressure who are cognit…

This phase 3 trial compares the experimental drug frexalimab to the approved drug teriflunomide in about 1,655 adults with relapsing multiple sclerosis. The main goal is to see if frexalimab reduces the number of relapses more effectively. Participants receive either frexalimab i…

This study tests a single-dose gene therapy called LY3884963 in 35 people with frontotemporal dementia caused by GRN gene mutations. The therapy aims to raise levels of a missing protein (progranulin) in the brain. Participants receive the treatment via injection into the fluid a…

This study tests whether ocrelizumab is safer and more effective than fingolimod for children and adolescents (ages 10 to under 18) with relapsing-remitting multiple sclerosis. Participants receive either drug and are monitored for relapses and brain lesions over at least 24 week…

This study tests a personalized antisense oligonucleotide drug designed for a single person with ALS caused by a specific TARDBP gene mutation. The drug aims to reduce harmful TDP-43 protein and slow disease progression. The participant's clinical function, survival, and biomarke…

This Phase 1 trial compares a new drug called RPH-035 to the approved MS drug Ocrevus. The study involves 180 adults with relapsing-remitting or secondary progressive multiple sclerosis who have flare-ups. Researchers are checking if RPH-035 behaves similarly in the body and has …

This Phase 3 trial tests an experimental drug called amlenetug in 401 people with multiple system atrophy (MSA), a rare and serious brain disorder. The goal is to see if the drug can slow the worsening of symptoms and improve survival. Participants receive either the drug or a pl…

This early-stage trial tests whether a special helmet that uses focused ultrasound can safely open the blood-brain barrier to deliver an anti-inflammatory drug (IVIg) directly to the motor cortex in people with ALS. Six participants will receive two doses of IVIg, with the second…

This study tests a personalized drug called an antisense oligonucleotide, designed specifically for people with ALS caused by a particular change in the CHCHD10 gene. The drug aims to slow or stop the disease by targeting the genetic root cause. The trial involves a small group o…

This trial tests a personalized medicine approach for a single person with amyotrophic lateral sclerosis (ALS) caused by a specific mutation in the CHCHD10 gene. The experimental drug, called an antisense oligonucleotide, is designed to target the genetic root of the disease. Res…

This study tests a custom-designed antisense oligonucleotide (ASO) drug for one person with ALS caused by a specific CHCHD10 gene variant. The drug aims to slow disease progression by targeting the genetic root of the condition. Researchers will monitor changes in muscle function…

This study tests a personalized medicine called an antisense oligonucleotide, designed specifically for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare genetic brain disorder. The treatment aims to reduce seizures and improve quality of life by targeting the …

This study tests a personalized medicine called an antisense oligonucleotide, designed specifically for one person with autosomal dominant leukodystrophy (ADLD), a rare genetic brain disease. The treatment aims to slow or stop the disease by targeting the underlying genetic mutat…

This study follows 175 people with spinal muscular atrophy who previously received the gene therapy Zolgensma in clinical trials. Researchers will monitor them for 5 years to track serious side effects and developmental milestones. The goal is to understand how safe and effective…

This early-stage trial tests a new drug called BIIB115 for spinal muscular atrophy (SMA), a genetic condition that causes muscle weakness. The study first gives a single dose to healthy adult volunteers to check safety, then moves to children with SMA who have already received th…

This study tests the drug risdiplam (Evrysdi) in infants up to 6 weeks old who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The goal is to see if early treatment can help them reach motor milestones like sitting without support. The trial involve…

This phase 2 trial tests whether the experimental drug VHB937 can slow the decline in function and delay the need for breathing support in people with early-stage ALS. About 251 participants will receive either VHB937 or a placebo for 40 weeks, followed by an open-label extension…

This early-stage trial tests an oral drug called verdiperstat in 64 people with semantic variant primary progressive aphasia (svPPA), a rare dementia that affects language. The study is double-blind and placebo-controlled, meaning some participants get the drug and some get a pla…

This study tests whether stimulating the vagus nerve through the ear, while doing a hand coordination task, can improve motor function in people with multiple sclerosis. Participants will receive either active or sham stimulation during 30-minute sessions over a month, with follo…

This study tests a gene therapy called PBKR03 for babies with early infantile Krabbe disease, a severe genetic disorder that damages the brain and nerves. The treatment delivers a working copy of the GALC gene to the brain and body. Researchers will check safety and find the best…

This phase 2 trial tests whether allopregnanolone, a natural hormone, can safely help repair the brain in people with early Alzheimer's disease. About 100 volunteers aged 55 to 80 will receive weekly infusions of the drug or a placebo for several months. Researchers will measure …

This Phase 2 study tests an experimental drug called BIIB080 in people with mild cognitive impairment or mild dementia due to Alzheimer's disease. The drug is injected into the fluid around the spinal cord every 12 or 24 weeks. Researchers want to see if it can slow the worsening…

This study planned to test whether injecting botulinum toxin (Botox) into the salivary glands could reduce drooling in people with true bulbar palsy, a condition that causes swallowing problems after a brain stem injury. The trial was designed to compare the injections against st…

This study planned to test a new CAR-T cell therapy called LCAR-AIO in adults with relapsed or treatment-resistant neurological autoimmune diseases, including multiple sclerosis and myasthenia gravis. The goal was to check safety and find the right dose. However, the trial was wi…

This early-stage trial tests whether a single infusion of donated mesenchymal stem cells is safe for children with cerebral adrenoleukodystrophy (cALD), a rare and life-threatening brain disease. The stem cells are given as a temporary bridge to buy time before a more definitive …

This study looks at whether a one-year treatment with Ocrevus can improve walking and balance in people with relapsing multiple sclerosis, compared to other standard treatments. Sixty adults aged 18-65 who can walk at least 25 feet will be split into two groups. Their walking abi…

This clinical trial is testing whether dimethyl fumarate, a drug already used for multiple sclerosis, can improve balance and walking in adults with adrenomyeloneuropathy (AMN), a rare nerve disease. Forty participants will take either the drug or a placebo daily for 36 months, w…

This phase 2 trial tests whether leuprolide (Eligard), a drug that lowers certain hormones, can slow memory and thinking decline in 180 women with mild Alzheimer's or mild cognitive impairment. All participants are already taking donepezil. The study compares leuprolide injection…

This study tests a gene therapy called vesemnogene lantuparvovec in about 20 people with spinal muscular atrophy (SMA), a genetic condition that causes muscle weakness. The therapy delivers a working copy of the SMN1 gene to help muscles work better. The main goal is to check saf…

This study compares the standard fixed-interval dosing of ocrelizumab (every 24 weeks) with a personalized approach where infusions are given only when B cell levels rise above a certain threshold. The goal is to see if the personalized schedule is just as good at preventing rela…

This early-stage trial tests a one-time gene therapy called CLN-301 in 7 children aged 3 to 10 with CLN3 Batten disease, a rare genetic disorder that causes progressive loss of vision, movement, and thinking skills. The therapy delivers a working copy of the CLN3 gene directly in…

This study looks at whether the drug ofatumumab can slow down thinning of the retina (the light-sensitive layer at the back of the eye) in people with relapsing-remitting multiple sclerosis (MS). Researchers will follow 75 adults with MS who are either starting or already taking …

This study tests whether the drug rapamycin is safe and tolerable for older adults with mild memory problems or early Alzheimer's disease. About 40 participants will take rapamycin for 12 months while researchers monitor side effects and changes in memory and thinking. The goal i…

This study tests a one-time gene therapy infusion (FBX-101) given after a standard stem cell transplant in 6 children with infantile Krabbe disease, a severe genetic disorder affecting the nervous system. The therapy uses a harmless virus to deliver a working copy of the GALC gen…

This early study tests a single injection of a gene therapy called NTF001 in 12 people with ALS. The therapy aims to deliver a protein that supports nerve cell health. The main goal is to check safety, but researchers will also look for signs of benefit over 52 weeks.

This study tests whether adding taldefgrobep alfa to standard SMA treatments can improve muscle function in people with spinal muscular atrophy (SMA). About 269 participants, both walkers and non-walkers, will receive either the drug or a placebo for 48 weeks. The main goal is to…

This early-stage trial tests a new gene therapy called NKG001 in 21 children under 5 with spinal muscular atrophy (SMA). The therapy is given as a single dose, either through a vein or combined with a spinal injection. The main goal is to check safety and find the best dose, not …

This study follows about 200 people with relapsing-remitting multiple sclerosis (RRMS) who are starting ozanimod (Zeposia®) for the first time. Researchers want to see how long patients continue the medication in everyday practice and how well it controls their disease. The study…

This study looks at whether people with relapsing-remitting MS who have not had a relapse in the past year but have high levels of a nerve damage marker (NfL) in their blood would benefit from switching to the drug ofatumumab. About 136 participants will either switch to ofatumum…

This study follows about 1,900 people with relapsing multiple sclerosis who have already taken ofatumumab in a previous Novartis trial. Participants continue receiving ofatumumab injections every 4 weeks to monitor long-term safety, side effects, and how well the drug controls re…

This study tests a non-invasive device that uses low-frequency electromagnetic fields to improve communication between immune cells. 120 adults with lupus, rheumatoid arthritis, or multiple sclerosis will receive either active or sham sessions three times a week for 12 weeks. The…

This study tests a higher dose of nusinersen (Spinraza) in 45 teenagers and adults with spinal muscular atrophy (SMA) who cannot walk and have already taken risdiplam. Participants receive two 50 mg loading doses two weeks apart, then 28 mg every four months for about two years, …

This study tests whether adding telitacicept to standard therapy helps adults with refractory chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. About 76 participants will receive either standard care alone or standard c…

This early-phase trial tests an experimental drug called nL-FLVC-001 in a single person with posterior column ataxia with retinitis pigmentosa (PCARP), a rare genetic condition that causes vision loss and coordination problems. The drug is an antisense oligonucleotide injected in…

This study aimed to test a drug called BAC in people with Alzheimer's disease or vascular dementia. The goal was to see if it could improve thinking and memory, and to check for side effects. However, the trial was withdrawn before any participants were enrolled, so no results ar…

This study tests an experimental drug called BIA 28-6156 in people with Parkinson's disease who have a specific change in the GBA1 gene. The goal is to see if the drug can delay the worsening of movement-related daily living skills over 78 weeks. About 237 participants will recei…

This study tests two newer multiple sclerosis drugs, ofatumumab and siponimod, against an older one, fingolimod, in 129 children aged 10 to 17. The goal is to see if the newer drugs are at least as good at preventing MS relapses. Participants take one of the three drugs for two y…

This early-stage trial tests a gene therapy called PBFT02 for frontotemporal dementia (FTD) in people with specific genetic mutations. The therapy delivers a working copy of the GRN gene directly into the brain. The study involves 30 adults and primarily checks for safety and sid…

This study tests an experimental drug called frexalimab in people with a type of progressive multiple sclerosis (MS) that is no longer causing relapses. The goal is to see if the drug can delay worsening disability compared to a placebo. About 943 adults aged 18 to 60 are taking …

This phase 3 trial tests whether the oral drug masitinib can slow disability worsening in people with progressive multiple sclerosis who do not have relapses. About 800 participants will receive either masitinib or a placebo for 96 weeks. The main goal is to see if masitinib dela…

This study tests an oral drug called SKY-0515 in 120 adults with Huntington's disease. The goal is to see if it can lower harmful proteins in the blood, slow brain changes, and improve symptoms. Participants must be 25 or older with a confirmed genetic diagnosis and a certain lev…

This early-stage study tests whether a new drug, prosetin, is safe for people with ALS (Lou Gehrig's disease) and healthy volunteers. About 72 participants will receive either the drug or a placebo to check for side effects and how the drug moves through the body. The goal is to …

This study tests whether regular warm-water baths can improve blood sugar control and brain energy use in healthy adults aged 65 and older who are at risk for Alzheimer's disease. Over 10 weeks, 60 participants will soak in warm water three times a week. Researchers will measure …

This study tests whether blood plasma from young, healthy, and very fit donors is safe and can help people with early Alzheimer's disease. Sixty patients aged 50-75 will receive monthly transfusions of either this 'exercise plasma' or a saltwater placebo over a year. Researchers …

This Phase 2 trial is testing a new drug called NVG-2089 in 60 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system attacks nerves. The drug is designed to mimic a natural protein (IVIg) to reduce inflammation and improve nerve…

This study tests an experimental drug called Lu AF82422 in 64 people with multiple system atrophy (MSA), a rare and serious brain disease. The goal is to see if the drug can slow down the worsening of symptoms like movement problems and daily living difficulties. Participants rec…

This program offered vatiquinone, an experimental liquid medication, to patients with inherited mitochondrial diseases like Leigh syndrome who had already completed a previous safety study. The goal was to continue treatment for those who might benefit, but enrollment is now clos…

This study tests whether lecanemab can slow memory and thinking decline in people with early Alzheimer's disease. About 1,900 participants received either the drug or a placebo for 18 months, followed by an open-label extension where everyone can get lecanemab. The main goal is t…

This study tests whether high-dose nicotinamide (vitamin B3) is safe and can help people with dominant optic atrophy, a rare genetic disease that slowly damages the optic nerve and causes vision loss. Researchers will give 25 adults 3 grams of nicotinamide daily and monitor for s…

This phase 2 trial is testing whether a combination of two drugs, dasatinib and quercetin, is safe and feasible for people with early-stage Alzheimer's or mild cognitive impairment. The drugs aim to clear aging 'senescent' cells that may contribute to brain damage. 48 participant…

This phase 3 trial tests whether the drug tofersen can delay or prevent ALS in adults who carry a SOD1 gene mutation but have no symptoms yet. About 158 participants will receive either tofersen or a placebo, and researchers will track how many develop ALS within two years. The g…

This study looks at whether people over 50 with a stable, inactive form of secondary progressive multiple sclerosis can stop taking their disease-modifying drugs without getting worse. Researchers will track 250 participants for 2 years to see if stopping treatment leads to more …

This study looks at how often older adults (62+) who are worried about memory loss should take dance or music classes to boost brain health and physical fitness. Over 6 months, 165 participants will attend 1, 2, or 3 group classes per week. Researchers will measure changes in mem…

This study tests whether N-acetyl cysteine (NAC), a supplement, can protect the brain in people with progressive multiple sclerosis (MS). About 98 adults with primary or secondary progressive MS will receive either NAC or a placebo for 15 months. Researchers will measure brain sh…

This study looks at whether switching from anti-CD20 drugs (like ocrelizumab) to cladribine can help restore immune function and reduce infections in people with relapsing multiple sclerosis. About 70 participants will be followed for 2 years. The goal is to see if the switch imp…

This early-phase trial tests whether a patient's own bone marrow stem cells, injected into the spinal fluid, can repair nerve damage caused by progressive multiple sclerosis. The study involves 18 adults with secondary or primary progressive MS. Researchers will measure changes i…

This clinical trial tests whether ibudilast (MN-166), a drug previously used for asthma, can slow the progression of amyotrophic lateral sclerosis (ALS). The study involves 234 adults with ALS, who will receive either ibudilast or a placebo for 12 months, followed by a 6-month op…

This study looks at whether terazosin, a drug usually used for high blood pressure, can slow the progression of Parkinson's disease. Researchers are tracking changes in heart and brain scans of 15 people who are either in early stages or at high risk for Parkinson's. The goal is …

This phase 3 study tests an oral medication called IMU-838 against a placebo in about 1,100 adults with relapsing multiple sclerosis (MS). The goal is to see if the drug can reduce the number of relapses and new brain lesions over 72 weeks. Participants must be 18-55 years old wi…

This Phase 3 trial tests whether IMU-838 (vidofludimus calcium) can reduce relapses and brain lesions in adults with relapsing multiple sclerosis. Over 1,100 participants are randomly assigned to receive either the drug or a placebo for up to 72 weeks. The study is active but no …

This phase 3 trial tests whether ocrelizumab (Ocrevus) can slow disability progression in adults with primary progressive multiple sclerosis (PPMS). Over 1,000 participants receive either the drug or a placebo. The main goal is to see if the drug delays worsening of hand function…

This Phase 2 trial tests whether a sleep-deepening drug (lower-sodium oxybate) or a nerve-stimulating device (non-invasive vagus nerve stimulation), or both, can help clear amyloid-beta protein from the brain in people with cerebral amyloid angiopathy (CAA). Sixty participants wi…

This study tests whether a smartphone app that coaches older adults to eat more protein can help them maintain muscle mass and strength. Researchers will enroll 140 participants who are open to changing their diet and using an app. The app provides personalized nutritional coachi…

This Phase 2 trial tests whether infusions of special immune cells (tolerogenic dendritic cells) can reduce brain lesions and relapses in people with relapsing-remitting multiple sclerosis. The 45 participants also take standard MS drugs. The study aims to see if this cell therap…

This study tests whether olive pomace oil, a type of olive oil, can lower brain inflammation in people with early-stage Alzheimer's. Researchers will give 40 Alzheimer's patients and 40 healthy adults meals containing either pomace oil or a different oil, then measure blood marke…

This study is testing whether the drug ocrelizumab (Ocrevus) can improve signs of inflammation in the spinal fluid of people newly diagnosed with relapsing multiple sclerosis (MS) or a high-risk first attack (clinically isolated syndrome). Thirty participants will receive ocreliz…

This study tests a program that uses a smartphone app, an activity tracker, phone coaching, and rewards to help adults in rural Kentucky eat more fruits and vegetables, cut down on fat, get more exercise, and spend less time on screens. About 279 participants will use the app and…

This study tests whether the drug tocilizumab can safely prevent or delay relapses in people with MOGAD, a rare autoimmune disease that attacks the nervous system. About 102 participants aged 12 and older who have had at least one relapse in the past year will receive either toci…

This early-stage study tests a one-time gene therapy injection into the spinal fluid of children aged 1-18 with CLN7 Batten disease, a rare and fatal genetic brain disorder. The main goal is to check safety, but researchers will also measure changes in movement, thinking, and vis…

This study tests a new drug called NX210c in 80 adults with ALS, a nerve disease that weakens muscles over time. Participants receive multiple IV infusions of the drug or a placebo to see if it slows the disease and is safe. The main focus is on changes in blood markers that refl…

This study is an open-label extension for people with early amyotrophic lateral sclerosis (ALS) who completed a previous placebo-controlled trial. Participants will take a daily oral dose of CNM-Au8, a suspension of gold nanocrystals, to see if it safely slows disease progression…

This study follows 20 adults with spinal muscular atrophy (SMA) type II who are already taking SPINRAZA. Researchers will measure motor function using a 32-point scale over 27 months to see if the drug helps maintain or improve movement. The goal is to better understand how SPINR…

This early-phase trial tests a single infusion of a gene therapy called FBX-101 in 9 people with Krabbe disease who have already received a stem cell transplant. The therapy uses a harmless virus to deliver a working copy of the GALC gene, aiming to improve motor function and saf…

This study tests a stem cell treatment (HB-adMSCs) for people with relapsing-remitting multiple sclerosis. The goal is to see if multiple infusions can improve quality of life and slow disability. Ten adults who previously received a placebo in an earlier trial will receive the t…

This study looks at the long-term safety and effects of the drug votoplam in people with Huntington's disease. About 144 participants who finished a previous votoplam study will take part. The goal is to see how the drug affects Huntington's protein levels and brain changes over …

This study tests whether treating severe gum disease can slow down Alzheimer's disease. Researchers will give 26 people with both conditions deep dental cleaning, extractions if needed, and oral hygiene training. Over 24 months, they will track memory, thinking skills, and brain …

This study tests a single dose of AVASPA gene therapy given directly into the brain of children with Canavan disease, a rare and severe genetic disorder that damages white matter. The therapy aims to restore a missing enzyme to help the brain produce myelin and slow disease progr…

This Phase 2 trial tests whether sabirnetug, given as an IV infusion every four weeks, can slow cognitive and functional decline in people with early Alzheimer's disease. About 542 participants will receive either sabirnetug or a placebo. The main outcome is change in a combined …

This study tests a custom-made drug called an antisense oligonucleotide in a single person with TUBB4A-related leukodystrophy, a rare genetic disorder that affects the brain's white matter. The drug is designed to target the specific genetic mutation causing the disease. Research…

This study follows 7 people who previously received a gene therapy called AXO-AAV-GM2 for Tay-Sachs or Sandhoff disease — rare, fatal genetic disorders that destroy nerve cells. Researchers will track them for up to 5 years to see if the treatment remains safe and whether it help…

This study follows 10 people with CLN6 Batten disease who received a single dose of gene therapy (AT-GTX-501) in an earlier trial. Researchers are checking long-term safety and how the disease progresses over time. No new treatment is given in this follow-up.

This early-phase trial tests a substance made from stem cells from baby teeth (SHED-CM) in 10 people with ALS. The goal is to see if it is safe and if it might slow the disease. Participants receive the treatment intravenously over 12 weeks, with follow-up for 4 more weeks.

This trial tests whether a person's own stem cells, taken from fat tissue and given back through an IV, can safely improve quality of life and physical function in people with aging frailty. The study plans to enroll 200 adults aged 40 to 90 who have lost energy and exercise tole…

This study tests whether a patient's own fat cells, processed into a special mixture called stromal vascular fraction, can safely improve quality of life and slow nerve damage in multiple sclerosis. About 100 adults with stable MS who have lasting nerve problems will receive an I…

This study tests a drug called BIIB017 (Plegridy) in teenagers aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). It compares Plegridy to another MS drug, Avonex, to see which is safer and more effective at reducing relapses. The trial involves 152 participants and i…

Researchers at Mayo Clinic are testing whether advanced PET and MRI brain scans can measure inflammation in people with multiple sclerosis and other inflammatory demyelinating diseases. The study includes about 200 participants, both patients and healthy controls. Participants re…

This trial tests an experimental imaging tracer called [11C]-CS1P1, which is designed to attach to a protein involved in brain inflammation. The study will first check the tracer's safety and how it moves through the body in healthy volunteers, then compare its signals in people …

This study investigates whether a combination of skin biopsies, speech analysis, and ultra-high field 7T MRI can detect early signs of Parkinson's disease and dementia with Lewy bodies. It focuses on people with a specific type of REM sleep behavior disorder triggered by serotone…

This study tests an AI tool called AIDP that analyzes MRI scans to help diagnose Parkinson's disease and two similar conditions (MSA and PSP). Researchers at 21 sites will compare the AI's diagnosis to that of movement disorder specialists. The goal is to see if the tool can impr…

This study tests whether a special heart scan using a radioactive drug called 123I-MIBG can help identify Lewy body disease, a type of dementia that also affects movement and sleep. Researchers will compare scan results with clinical diagnoses in 50 people who have conditions lik…

ScreenPlus is a large pilot program that offers families the option to have their newborn screened for a panel of rare genetic disorders, in addition to standard newborn screening. The study aims to screen 100,000 infants born at eight hospitals in New York. Researchers will eval…

This study tests whether smartphone usage data can help tell the difference between normal memory complaints, mild cognitive decline, and Alzheimer's disease. Researchers will collect data from 90 participants' phones over three months. If it works, it could offer a simple, low-c…

This study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…

This study uses special brain scans (PET imaging) to measure amyloid buildup—a protein linked to Alzheimer's—in healthy older adults, people with mild memory problems, and those with dementia. Participants receive scans every 2-3 years for up to 20 years to see how amyloid change…

This study explores whether a self-administered digital test called eSAGE, combined with information from electronic health records and machine learning, can help detect early signs of cognitive impairment, including dementia and Alzheimer's disease. Researchers will analyze data…

This study tests a new radioactive tracer called Fluselenamyl for PET scans to detect beta-amyloid plaques in the brain, a hallmark of Alzheimer's disease. Researchers will check its safety and how well it works in 60 healthy volunteers and people with mild cognitive impairment o…

This study aimed to see if a special fMRI scan (fMRI-SAM) could help detect Alzheimer's disease early. Researchers planned to compare brain activity in 25 people with Alzheimer's, 25 with mild memory problems (MCI), and 60 healthy adults. The goal was to find differences that mig…

This early-phase study tests whether a single injection of pramlintide, a diabetes drug, can temporarily increase levels of Alzheimer's-related proteins in the blood, potentially revealing early signs of the disease. Researchers will measure changes in beta-amyloid and tau protei…

This study compares a new ultra-high resolution PET/CT scanner, the NeuroEXPLORER, with standard clinical PET/CT scanners for imaging the head and neck. Researchers aim to see if the new device provides more detailed images to improve diagnosis of conditions like dementia, Parkin…

Stanford University is developing a mobile app that uses video of a simple physical test (the Short Physical Performance Battery) to assess physical and cognitive function in older adults. The study will collect video data from 30 healthy volunteers to train the app's AI. The goa…

This study is testing whether a simple saliva sample can help diagnose amyotrophic lateral sclerosis (ALS). Researchers will analyze RNA in the saliva of 653 people, including ALS patients and healthy volunteers. If the test works, it could offer a faster, less invasive way to di…

This study is testing whether a specific feature on brain MRI scans—called the central vein sign—can improve the accuracy of multiple sclerosis (MS) diagnosis. Currently, up to 1 in 5 people diagnosed with MS are later found not to have the disease, leading to unnecessary and pot…

This study looks at whether measuring kappa free light chains (KFLC) in spinal fluid can replace the standard test (oligoclonal bands) for diagnosing multiple sclerosis (MS) and its early stage, clinically isolated syndrome (CIS). Researchers will compare both tests in over 1,100…

This study aims to create a simple test battery to determine fall risk in people with neuromuscular disorders, such as muscular dystrophy or ALS. Researchers will assess 108 participants using several physical tests like walking, standing, and rising from a chair. The goal is to …

This study tests whether combining aerobic exercise with cognitive training, delivered via interactive 'exergames' at home, can help prevent Alzheimer's in older adults who have memory concerns but no diagnosed dementia. Participants will be randomly assigned to either an exergam…

This trial tests whether a specific type of computerized cognitive training, called speed-of-processing training, can delay the onset of mild cognitive impairment or dementia in adults aged 65 and older. Participants will complete 45 sessions of either the training or a general c…

This study looks at whether long-term, high-intensity indoor cycling can slow or delay Alzheimer's-related brain changes in healthy older adults (ages 65-80) who carry the APOE ε4 gene, a known risk factor. Participants, who are currently inactive, will use a Peloton bike at home…

This study tests whether metformin, a drug used for diabetes, can prevent Alzheimer's dementia in people with mild cognitive impairment (MCI). Over 18 months, 326 overweight adults aged 55-90 with MCI will receive either metformin or a placebo. Researchers will track memory, brai…

This 7-year study tests whether a combination of mild electrical brain stimulation (tDCS) and computer-based memory exercises can slow mental decline and prevent Alzheimer's dementia. It involves 375 older adults with mild cognitive impairment or depression (both risk factors for…

This study tests if a drug called dalargin can prevent serious organ problems like kidney injury, lung failure, or heart damage after major abdominal surgery. About 200 adults having high-risk surgery will get either dalargin or a placebo for 3 days. The goal is to see if dalargi…

This study is testing whether an online course can help people with multiple sclerosis, long COVID, fibromyalgia, or cancer-related fatigue adopt healthier diets and self-care habits. Researchers will measure changes in quality of life, fatigue, and mental health. The goal is to …

This study tests whether two special diets—a modified Paleolithic elimination diet and a time-restricted ketogenic diet—can improve quality of life, fatigue, and mood in 162 people with relapsing-remitting multiple sclerosis. Participants are assigned to one of the diets or stand…

Guillain-Barré syndrome can leave people with weak arms and hands, making daily tasks hard. This trial tests whether adding robot-assisted arm training to usual therapy helps adults in the sub-acute phase of recovery. Participants use the Armeo Power 2 exoskeleton for 20 sessions…

ALS weakens the muscles that control breathing, and doctors often turn to a ventilator as the disease progresses. This trial tests whether using a pressure-relaxer device early, which helps expand the chest and clear the airways, can slow the loss of lung function. Adults with AL…

This study tests whether masupirdine, a daily tablet, can safely reduce agitation in people with Alzheimer's dementia. About 375 participants will receive either masupirdine or a placebo. The main goal is to see if the drug improves agitation symptoms, which can include aggressio…

This study tests a new type of cycling called eccentric cycling for people with multiple sclerosis. Researchers want to see if it improves muscle strength, walking ability, fatigue, and quality of life better than standard cycling. Sixty adults with MS who can walk independently …

This trial tests a wearable device that uses mild electrical pulses to stimulate the leg muscles of people with multiple sclerosis who have foot drop. The goal is to see if using the device for several months improves walking quality, physical activity, and participation in daily…

Researchers are testing whether a virtual walking program can reduce chronic pain and psychological distress in people with severe mobility impairment, mostly from spinal cord injuries or polio. Participants wear a head-mounted display and use a controller to guide an avatar thro…

This early study tests a virtual reality rehabilitation device for children with spinal muscular atrophy (SMA), a genetic condition that causes progressive muscle weakness. The device uses games, muscle sensors, and a grip-strength ball to make home exercises more engaging. Resea…

This study tests a smartphone app called MS CATCH that lets people with multiple sclerosis regularly report their mood to their neurologist. The goal is to improve how doctors screen and treat depression in MS. About 100 adults with MS and mild-to-moderate depression are taking p…

Researchers at Baylor College of Medicine are testing whether a supplement combination called GlyNAC can improve brain energy use and reduce inflammation in people with Alzheimer's disease. The trial enrolls 52 adults aged 55 to 85 who have progressive memory loss and amyloid pla…

This study from Yale University will test whether listening to live music can reduce anxiety and improve brain activity in people with early Alzheimer's disease, dementia, or mild cognitive impairment, along with their caregivers. Sixty pairs (patient and caregiver) will attend b…

This study tests two online programs designed to help people with multiple sclerosis (MS) understand and manage their fatigue. Researchers will enroll 2,000 adults with MS across the U.S., including veterans, and compare the programs to usual care alone. The goal is to find pract…

This study tests whether a six-week, nurse-led virtual group program can help adult women with Multiple Sclerosis (MS) find more meaning and purpose in life, and improve their quality of life. Participants attend weekly online group sessions focused on reflection and values explo…

This pilot trial tests whether people with multiple sclerosis can safely and satisfactorily use a telemedicine platform for balance rehabilitation at home. After completing intensive in-hospital rehabilitation, participants either follow a 12-week home telerehabilitation program …

This study tests a new drug called CST-3056 in 12 adults with neurogenic orthostatic hypotension (a sharp drop in blood pressure when standing) caused by Parkinson's disease or pure autonomic failure. The goal is to see if the drug can improve blood pressure and reduce symptoms l…

This study tests a non-invasive technique called Low Intensity Focused Ultrasound Pulsation (LIFUP) to see if it can safely increase brain activity and improve memory in people with mild cognitive impairment or mild Alzheimer's disease. Participants will receive ultrasound to a k…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study tests a mobile telehealth app called Brain CareNotes designed to help unpaid Hispanic caregivers manage challenging behaviors in people with Alzheimer's or related dementias. The app offers coaching and tools to handle symptoms like agitation or wandering. Researchers …

This study tests a personalized workplace intervention for 124 Dutch workers with Parkinson's disease, cerebellar ataxia, hereditary spastic paraparesis, or slowly progressive neuromuscular/mitochondrial disorders. A trained facilitator helps employees and their managers identify…

This study tests a personal health app called MS FIT that lets people with multiple sclerosis log falls and near-falls, view their health data, and share it with their doctor. The goal is to improve communication about fall risks and provide educational tips. About 100 participan…

This study looks at whether starting noninvasive ventilation (a breathing mask) at home works as well as starting it in the hospital for people with ALS who have chronic breathing problems. Researchers will track how many hours patients use the device and whether their blood carb…

This study explores whether a type of improvised music, designed with calming sound parameters, can reduce anxiety in people with Alzheimer's disease and in healthy adults. Researchers will measure changes in anxiety scores, blood pressure, and heart rate before and after listeni…

This study is testing the long-term safety of a drug called ML007C-MA for people with Alzheimer's disease who also have hallucinations and delusions. About 210 adults who completed a previous study will take the drug twice daily for up to 52 weeks. The goal is to see if the drug …

This study tests an 8-week program that helps people with mild dementia and their caregivers identify and use their strengths. The program includes workshops and a biography activity led by trained volunteers. Researchers will measure changes in thinking skills and caregiver conf…

This trial tests whether custom-designed sensorimotor insoles, worn daily for six months, can improve balance and walking in people with multiple sclerosis. Fifty adults with MS (mild to moderate disability) will be randomly assigned to receive the insoles or continue their usual…

This study tests a non-invasive technique called temporal interference stimulation (TIS) that uses weak electrical fields to target deep brain areas involved in memory and emotion. Researchers will give two weeks of TIS to people with Alzheimer's disease who also have depression,…

This study tests whether a wearable device, used at home alongside pelvic floor therapy, can help people with multiple sclerosis manage bladder problems. Twenty women with MS will use the device for three months. The main goal is to see if the approach is practical and easy to us…

This study tests whether a 24-week physical therapy program can help people with multiple sclerosis become more physically active. Forty participants will receive tailored exercise support and education. The goal is to see if this approach is feasible and helps manage MS symptoms…

This study tests whether a device that plays brief, soft sounds during deep sleep can enhance brain wave activity in people with mild cognitive impairment due to Alzheimer's disease. Participants use the device at home each night for three months, with an optional three-month ext…

This pilot study explores whether non-invasive electrical stimulation of the spinal cord, combined with hand and arm exercises, can improve upper limb function in people with multiple sclerosis. Participants use a home device with help from a partner over 8 weeks. The study focus…

This pilot study tests whether one-on-one peer support sessions can help people with relapsing-remitting multiple sclerosis stay on their prescribed medications. Sixty adults will be randomly assigned to receive either standard care or three hour-long sessions with a trained peer…

This study planned to test whether automated music therapy could help manage agitation and sleep problems in people with severe Alzheimer's living in nursing homes. An actigraph would detect sleep issues and trigger music sessions automatically. The trial was withdrawn before any…

This study looks at whether special video games (serious games) that combine physical and mental exercises are a good value for managing Alzheimer's disease. About 136 people with mild to moderate Alzheimer's will either play these games with a therapist or receive usual care. Re…

This study tests whether a guided internet-based physical activity program can improve cognitive processing speed in people with multiple sclerosis. 280 participants who have mild walking difficulties and slowed thinking will be randomly assigned to either the exercise program or…

This study tests if a gentle, non-invasive nerve stimulation device can help manage symptoms of multiple sclerosis (MS), like fatigue and pain. Thirty women with MS will use the device at home for a few weeks. The goal is to see if it's practical and if it reduces symptom burden,…

This study tests a new way to match dementia caregivers with each other for emotional support using a computer algorithm. Researchers want to see if matching based on personal preferences leads to better satisfaction and less stress than random matching. About 355 caregivers of p…

This phase 2 trial tests whether a single low-dose ketamine infusion can reduce fatigue in people with multiple sclerosis. About 110 adults with MS-related fatigue will receive either ketamine or a mild sedative (midazolam) as a placebo. The study measures changes in fatigue scor…

This study was designed to test whether a reusable pouch called DoddleBags could help people with Huntington's disease eat more easily and safely. The pouch holds pureed food and can be used with an anti-choking cap or spoon attachment. The trial was withdrawn before any particip…

This study tests whether using a device that delivers light and sound stimulation for 60 minutes each day is safe and practical for people with mild Alzheimer's. Fifteen participants will use the device at home for 6 to 9 months. The main goals are to see if people can stick with…

This study tests whether adding a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) to speech therapy can improve language skills in people with primary progressive aphasia (PPA), a condition that slowly damages language areas of the brain. A…

This study tests whether combining transcranial magnetic stimulation (TMS) with virtual reality exercises and physical therapy can improve symptoms like balance, fatigue, and thinking in people with multiple sclerosis. Thirty participants will receive both real and sham TMS in a …

This pilot study aimed to test whether immersive virtual reality (VR) exercises could help people with multiple sclerosis who experience dizziness, balance issues, and fatigue. Participants would have been randomly assigned to either VR-based vestibular rehab or conventional exer…

This study tests whether a 12-week strength and functional exercise program, done at home via video calls with a physiotherapist, can improve walking, balance, and daily life in people with Hereditary Spastic Paraplegia (HSP). Twenty participants aged 16 to 70 will each experienc…

This pilot study tested whether a non-invasive brain stimulation technique called tDCS could improve cognitive and motor functions in older adults with mild Alzheimer's disease living in supportive housing. Eleven participants received either real or sham stimulation over 10 sess…

This study tests a 6-week online program called Learning Skills Together for family caregivers of people with Alzheimer's or related dementias. The program includes weekly group discussions and a workbook covering topics like communication, medication management, and home safety.…

This study tests whether a non-invasive brain stimulation technique called paired associative stimulation (PAS) can improve memory and thinking in 150 older adults with mild cognitive impairment (MCI), a condition that often leads to Alzheimer's. Participants receive daily sessio…

This study looks at whether adding a daily 30-minute muscle stimulation session can improve pain control and quality of life for people who already have a spinal cord stimulator (BurstDR) for chronic back pain. Sixty adults with failed back surgery syndrome or persistent spinal p…

This study tests a cognitive rehabilitation program called CIRCuiTS, adapted for people with Multiple Sclerosis (MS). Twenty-four participants will either start the program right away or after a 13-week wait. The program involves up to 36 hours of therapist-led and independent se…

This study tests a structured care pathway for treating agitation and aggression in people with Alzheimer's disease. The pathway combines personalized activities with medication guidelines to reduce symptoms and avoid using too many drugs. Researchers will compare this approach t…

This study tests a tablet-based app called the Digital Memory Notebook (DMN) to help older adults with mild memory problems or early Alzheimer's manage everyday tasks like appointments and medications. Twenty participants will learn to use the app over six weekly sessions, then c…

This study looks at whether improving diet quality and reducing calories can help physical function, thinking, pain, fatigue, mood, and anxiety in 100 adults with relapsing-remitting or secondary progressive multiple sclerosis. Participants receive prepared meals and behavioral s…

This small, early-stage study tested a high-CBD, low-THC liquid spray for 8 weeks in 12 older adults with mild cognitive impairment or mild-to-moderate Alzheimer's who also had significant anxiety or agitation. The goal was to see if the treatment could reduce these behavioral sy…

This study tests whether a 4-week telerehabilitation program can improve balance and quality of life in 36 people with multiple sclerosis or Parkinson's disease. Participants do balance exercises at home while monitored by a hospital physiotherapist. The results are compared to s…

This study tests whether a 9-week online cognitive behavioral therapy program can improve sleep in people with multiple sclerosis (MS). About 550 participants in Norway will either receive the digital therapy or digital education about insomnia. The main goal is to see if the the…

This study tests whether educational programs about exercise, Mediterranean diet, and mental strategies can improve quality of life and reduce fatigue in women with relapsing-remitting multiple sclerosis. About 60 participants will be assigned to either supervised in-person sessi…

This study tests if learning memory techniques (like mnemonics) can improve thinking and memory in adults over 50 who have mild memory concerns. 80 participants will either take memory training or just get information. The goal is to see if training helps and if benefits last up …

This study looks at whether online community support and telemedicine can improve quality of life for people with Parkinson's disease, Lewy body dementia, and related conditions, as well as their caregivers. About 632 participants will receive palliative care training for their d…

This study tests a set of virtual reality exergames in the Metaverse to help people with neurological conditions like multiple sclerosis, Parkinson's disease, stroke, and traumatic brain injury improve their cognitive skills. 25 participants will try games like virtual cooking an…

This study tests whether virtual reality (VR) reminiscence therapy can reduce behavioral problems and improve quality of life in 50 nursing home residents with mild to moderate Alzheimer's disease. Participants will use VR to explore familiar heritage sites, aiming to trigger pos…

This study is testing a device called MemorEM, which is a cap that sends low-level electromagnetic waves to the head. The goal is to get feedback from 1,000 patients with neurological diseases like Alzheimer's or Parkinson's, and their caregivers, on how easy the device is to use…

This study tests a program called FACE-Rare, designed to support family caregivers of children with rare, life-limiting diseases. The program includes three sessions to help families prepare for future medical decisions and improve their quality of life. Researchers will compare …

This study will test whether taking a daily DHA (omega-3) supplement and doing therapeutic exercise three times a week can improve strength, fatigue, thinking, and quality of life in 100 people with multiple sclerosis. Participants will be randomly assigned to one of four groups:…

This study is testing whether a robotic exoskeleton called Atalante can safely help people with ALS maintain their ability to walk. The idea is that the suit provides natural leg movements and feedback to the brain, which may slow down walking decline. About 20 adults with slow-p…

This early-stage study tests whether a novel light therapy, designed to reset the body's internal clock, is safe and can reduce fatigue in people with progressive multiple sclerosis. Twenty participants will receive the light therapy while researchers monitor side effects and mea…

This study tests a 6-month online program designed to help people with multiple sclerosis become more physically active. Participants receive interactive video lessons, a step tracker, and one-on-one video chats with a coach. The goal is to see if the program increases daily acti…

This study tests a new, team-based rehabilitation program for 125 working-age adults with persistent physical symptoms and chronic fatigue. The program includes doctors, therapists, and counselors who work together to help patients manage their symptoms and improve daily function…

This pilot study tests a home-based program called HOBSCOTCH, designed to help people with multiple sclerosis manage memory and thinking problems. Eleven participants will attend virtual coaching sessions and complete questionnaires about their quality of life and cognitive funct…

This study tests a specially designed garment for elderly dementia patients who have incontinence and often remove their protective pads. The goal is to see if a more dignified, comfortable garment can improve satisfaction for patients and caregivers. Forty participants will be r…

This study tests whether N-acetyl cysteine (NAC), a common antioxidant supplement, can improve brain function and reduce inflammation in people with multiple sclerosis (MS). Researchers will use brain scans to measure changes in metabolism and inflammation. The study enrolls 55 a…

This study tests whether a tele-rehabilitation program is safe and beneficial for people with multiple sclerosis (MS). 75 participants will do three online rehab sessions per week. Researchers will track side effects, quality of life, walking ability, mood, and fatigue, comparing…

This phase 3 study tests a drug called ampreloxetine for people with multiple system atrophy (MSA) who experience dizziness and fainting due to low blood pressure when standing. About 102 adults with MSA will take the drug for 20 weeks, then some will switch to placebo to see if …

This study develops and tests a decision-making program designed specifically for African American adult daughters who make healthcare choices for their parents with dementia. The program focuses on communication, problem-solving, and understanding the healthcare system, all whil…

Researchers are studying how people with relapsing multiple sclerosis use ofatumumab in everyday practice in Germany and Japan. The study looks at insurance claims from about 5,000 adults to see how many stay on the treatment and how regularly they take it. It also tracks how oft…

Researchers are checking whether tests of muscle strength, walking, balance, and fine motor skills give consistent results in people with polyneuropathy. About 520 adults with various forms of nerve damage, plus healthy volunteers, take part. Participants complete physical tests,…

This study collects health information and test results from 317 people at high risk for pancreatic cancer, including those with cysts, genetic syndromes, or other risk factors. Researchers aim to build a database to find better ways to detect the disease early or prevent it. No …

This study follows 25 people with spinocerebellar ataxia type 7 (SCA7) for up to 5 years to learn how the disease changes vision, coordination, and thinking. Participants will have yearly eye exams, brain scans, and neurological tests. No treatment is given; the goal is to gather…

This study follows 285 older adults with Alzheimer's or mild cognitive impairment to learn how they make decisions about aging in place or moving to long-term care. Researchers will track planning and preferences over time. No treatment or intervention is being tested.

This study is a registry that collects information on up to 600 children in China with spinal muscular atrophy (SMA). It aims to describe how the disease progresses and how treatments are used in everyday medical practice. The study does not test a new drug but gathers data to be…

This observational study will enroll 100,000 people over age 45 to track early signs of Alzheimer's and Parkinson's using smartphone-based tests, genetic data, and brain scans. Researchers aim to develop better ways to identify who is at risk before symptoms worsen. Participants …

Researchers are collecting blood and skin samples from people with ALS, people with MS, and healthy volunteers. They turn skin cells into stem cells and grow them into 3D organoids that mimic the brain and spinal cord. The goal is to see whether secretions from human amniotic mes…

This long-term study looks at children and adults with inherited nerve and muscle disorders that start early in life, like muscular dystrophy. Researchers will track symptoms over time and collect genetic samples from affected individuals, their family members, and healthy volunt…

This study compares two different radioactive tracers used in PET scans to measure tau tangles in the brain, a hallmark of Alzheimer's disease. Researchers will scan over 800 participants with either Flortaucipir or MK-6240 to see how well they work over time. The goal is to harm…

Researchers are testing whether combining genetic data, blood or brain biomarkers, and detailed thinking and memory tests can better predict who might develop Alzheimer's disease. The study follows 200 adults with either mild memory complaints or early cognitive decline over two …

Researchers are studying the natural fidgety movements of infants to see if these movements can help predict cerebral palsy and other developmental issues. They will follow 350 babies, including healthy full-term infants and those at higher risk due to medical conditions, trackin…

Researchers are testing a muscle biopsy method that uses mild electrical stimulation to sample the junction where nerves meet muscle. The goal is to see if this technique helps distinguish between inclusion body myositis and motor neuron disease, which can look alike. The study i…

This observational study follows about 2,400 people with relapsing-remitting multiple sclerosis (MS) across Germany for up to six years. It asks whether loss of volume in the thalamus—a deep brain region—tracks with worsening disability, measured by the EDSS scale. Using standard…

This study follows 1,500 volunteers with normal memory, mild cognitive impairment, or Alzheimer's over several years. Researchers use brain scans, memory tests, and blood samples to track how the disease progresses. The goal is to find better ways to diagnose and treat Alzheimer'…

This study aims to find early markers of Parkinson's disease, multiple system atrophy, and Lewy body dementia by analyzing samples from the nose, blood, and urine. Researchers will compare results from 180 people with these conditions and healthy volunteers. The goal is to improv…

This study aims to find biological markers (biosignatures) in people with ALS and FTD to make diagnosis more precise. Researchers will analyze samples like spinal fluid, skin, and tears from 230 participants using advanced techniques. The goal is to create a 'disease fingerprint'…

This study looks back at the medical records of 800 people who were hospitalized with dangerously low sodium levels (≤110 mmol/L). Researchers want to learn how often serious brain complications like swelling or nerve damage occur, and how treatment affects these risks. No new tr…

This study follows 20,000 healthy Chinese adults aged 40-75 living at various altitudes to see if chronic low oxygen levels increase the risk of multiple system atrophy (MSA), a rare and fatal brain disease. Participants undergo checkups and overnight oxygen monitoring, then are …

This study explores why some people with multiple sclerosis (MS) improve more than others with rehabilitation. Researchers will test whether thinking speed and the integrity of specific brain pathways influence how well participants learn a new balance task. About 146 adults with…

This observational study follows up to 3,000 people who were previously screened for anti-amyloid Alzheimer's prevention trials but did not qualify based on amyloid levels. Over about 6 years, researchers will track changes in blood biomarkers, brain amyloid (via PET imaging), an…

This study follows 1,000 adults aged 50 and older to see how the health of their heart and blood vessels relates to early signs of Alzheimer's disease and brain aging. Researchers will use brain scans, memory tests, and blood or spinal fluid samples to look for connections betwee…

This program collects brain and other tissue samples from adults, including healthy individuals and those with memory disorders, to support research on Alzheimer's disease. Participants are typically enrolled in affiliated studies or approved on a case-by-case basis. The goal is …

This study looks at how much of the multiple sclerosis drug ofatumumab gets into breast milk. About 24 women with relapsing MS who are breastfeeding and starting or restarting ofatumumab will provide milk samples. The goal is to measure drug concentrations, which may help guide f…

This study uses PET imaging to measure two key proteins in the brain—amyloid and tau—that are hallmarks of Alzheimer's disease. Researchers will follow 120 participants over five years, including people with normal aging, mild cognitive impairment, and dementia, to see how these …

This study investigates whether people with neurodegenerative diseases—like Alzheimer's, Parkinson's, or ALS—show changes in behavior, social circumstances, or health before and after their diagnosis. Researchers will compare the records of over 61,000 patients with those of matc…

This study explores whether a brief, moderate-intensity walk can alter brain function and blood flow in people with multiple sclerosis. Participants will undergo MRI scans before and after either treadmill or overground walking at a brisk pace. The goal is to see if even a single…

This study is a nationwide registry in China that will follow adults with a genetic form of spinal muscular atrophy (SMA). The goal is to describe how the disease naturally progresses over time and how disease-modifying treatments are used in real-world settings. By collecting da…

This study investigates how the brain makes decisions when visual information is uncertain, focusing on the roles of the basal ganglia and cerebellum. Researchers will compare healthy adults with patients who have Parkinson's disease, dystonia, or cerebellar damage, and will test…

This study tests whether everyday rehabilitation therapy sessions can be recorded and measured more objectively using wrist-worn sensors, a video camera, and an audio recorder. Adults with neurological conditions like stroke, Parkinson's disease, or spinal cord injury will wear t…

This study is a patient registry that will follow people of any age with bile acid synthesis disorders who are treated with Cholbam (cholic acid). The goal is to collect information over 10 years on how the drug performs in routine clinical care, including its safety, effectivene…

This study follows 850 people aged 40-64 with early-onset cognitive impairment to understand how Alzheimer's disease progresses. Participants undergo cognitive tests, brain scans, and genetic analysis, but no experimental treatment is given. The goal is to gather data that could …

This study investigates whether a combination of brain MRI scans, sleep recordings, and cognitive tests can track early brain changes in people with idiopathic REM sleep behavior disorder (iRBD), a condition that often precedes Parkinson's disease. Researchers will follow 50 peop…

This study uses advanced PET scans to investigate how brain inflammation and tau protein buildup affect synaptic density in people with Alzheimer's disease. Researchers will compare Alzheimer's patients to healthy controls over two years, tracking changes in these brain markers. …

This study looks at how Friedreich's ataxia, a genetic nerve disease, affects thinking skills like memory and problem-solving. Researchers will compare cognitive test results between people with the condition and healthy volunteers, and see if these results relate to the number o…

This study tests a program called Disaster PrepWise for caregivers of people with dementia. The program uses trained volunteers to help caregivers create emergency plans and build support networks. Researchers will measure whether the program improves caregivers' resilience and r…

This study tests a digital platform that combines an app for patients and a brain-scan analysis tool for doctors. The goal is to see if it helps monitor multiple sclerosis (MS) more easily in everyday care. About 500 people with relapsing-remitting MS will use the app and have th…

This study looks at how consistently doctors can identify paramagnetic rim lesions (PRLs) on MRI scans of people with multiple sclerosis. PRLs are a sign of more active and aggressive disease. By having experts from 15 centers review the same scans, the researchers aim to create …

This study follows 300 people with multiple sclerosis to see whether advanced MRI scans, eye tests, and blood markers can better predict when disability will worsen. Current tools are not accurate enough to guide early treatment for each individual. The researchers will compare t…

This study looks at how myotonic dystrophy types 1 and 2 affect the brain. About 100 adults aged 30-65 will have MRI scans, thinking and movement tests, and blood draws. Some will also have a spinal tap. The goal is to find brain changes that could be used as markers in future tr…

This observational study follows thousands of people with multiple sclerosis (MS) over many years to identify factors that predict how the disease will progress. Researchers collect detailed clinical data, MRI scans, and quality-of-life questionnaires from participants treated at…

This study looks at whether giving older adults (ages 60-79) personalized advice and extra support helps them follow brain-healthy habits like a Mediterranean diet, exercise, and staying socially active. Participants have mild memory concerns or are at risk for cognitive decline.…

This study is testing a web-based platform called LEAD that helps people in the early stages of Alzheimer's or dementia talk about and document their end-of-life care preferences. The goal is to make it easier for them and their care partners to feel confident in making future me…

This study uses a new, child-friendly brain imaging technique called OPM-MEG to understand how immune-related brain diseases (like autoimmune encephalitis and multiple sclerosis) and other brain conditions affect children aged 2 to 25. Standard scans often miss problems with memo…

This study investigates how a single high-fat meal (heavy cream) changes blood flow in the brain, and whether this effect differs based on a person's APOE gene variant — a known risk factor for Alzheimer's disease. Researchers will measure brain blood flow using MRI before and tw…

This study examines walking patterns in people with Parkinson's disease and similar neurological conditions, as well as healthy volunteers. Researchers aim to identify unique 'gait signatures'—speed-dependent measures of walking—that could help distinguish between different disor…

This study follows 20 people with a rare nerve disease called CMT4J for up to 2 years. Researchers will track symptoms and health changes to better understand how the disease progresses. The goal is to find better ways to measure the disease, which could help design future treatm…

This study looks at how many women with multiple sclerosis (MS) use the drug interferon-beta during the second and third trimesters of pregnancy in Finland and Sweden. Researchers want to know if there are enough cases to study whether the drug affects pregnancy outcomes like bir…

This study looks at two new ways to stage amyotrophic lateral sclerosis (ALS) based on key disease milestones. Researchers will check how well these systems work in 50 patients and see if adding a blood marker called neurofilament can improve tracking of the disease. The goal is …

This study aimed to see if Alzheimer's disease affects the nerves in the gut, similar to what happens in Parkinson's disease. Researchers planned to take extra colon biopsies during routine colonoscopies from people with Alzheimer's, Parkinson's, and healthy individuals to compar…

This study tests a short guide called the 'Jumpstart Guide' to help doctors have better conversations with dementia patients and their families about healthcare goals. Over 1,800 patients and their caregivers are taking part. Researchers will compare whether those whose doctors u…

This study aims to identify biomarkers—biological clues in the body—that can help distinguish between Parkinson's disease and similar conditions like progressive supranuclear palsy and multiple system atrophy. Researchers will follow people with early-stage parkinsonism and healt…

This study is observing 217 people with ALS and related conditions like frontotemporal dementia and hereditary spastic paraplegia. Researchers aim to connect each person's genetic makeup with their symptoms and find biological markers in blood and spinal fluid. No new treatments …

This study looks at people with ALS and similar diseases like frontotemporal dementia and hereditary spastic paraplegia. Researchers want to understand how genes affect the disease and find biological markers (biomarkers) to help develop future treatments. About 708 participants,…

This study investigates how genetic, lifestyle, and biological factors relate to memory and thinking problems in people over 60 with Alzheimer's disease, Parkinson's disease, or mild cognitive impairment. Researchers will use brain scans, spinal fluid and blood tests, and data fr…

This study looks at whether a blood test measuring a protein called neurofilament light (sNfL) can help doctors predict and manage disease activity in people with relapsing multiple sclerosis (MS). About 489 adults with MS in Germany will be observed for 24 months. The goal is to…

This study uses a special PET scan to look at tau protein buildup in the brains of African Americans who are either cognitively normal or have dementia. Researchers hope to learn how these brain changes differ across racial groups. The study involves 240 participants and uses a t…

This observational study is creating a large database of up to 96,000 people with multiple sclerosis and related conditions in Italy. Researchers will collect information on patient demographics, treatments, and disease progression over time. The goal is to better understand thes…

This study uses special brain scans (MRS) to measure two natural chemicals, GABA and glutathione, in people with Friedreich's Ataxia (FRDA). Researchers want to see if these chemicals can serve as reliable markers of the disease and how they change after taking the drug Omaveloxo…

This study tests a new radioactive compound called F 18 T807 that lights up tau tangles in the brain during a PET scan. Researchers want to see if the amount of tau relates to memory and thinking problems in people with a rare, inherited form of Alzheimer's disease. About 130 adu…

This study uses a radioactive tracer called [18F]MK-6240 to take detailed pictures of tau protein clumps in the brain, a hallmark of Alzheimer's disease. Researchers will scan 200 people from families with a rare genetic form of Alzheimer's to see how tau buildup changes over tim…

This study planned to see if mindfulness meditation using virtual reality could help people with ALS feel better emotionally and improve their quality of life. It was designed for adults with ALS who speak French. However, the study was withdrawn before enrolling any participants…

This study aimed to compare T cell populations between people with multiple sclerosis and healthy controls to better understand which immune cells attack the nerves. It was withdrawn before enrolling any participants, so no results are available. The goal was to learn more about …

This study will collect and analyze genetic data from 1000 people with suspected inherited metabolic diseases, including conditions like epilepsy and mitochondrial disorders. Researchers at Karolinska University Hospital aim to improve diagnosis by using advanced genetic testing …

This study follows 640 adults with normal cognition, mild cognitive impairment, or Alzheimer's disease to track brain changes over time. Researchers use advanced brain scans and genetic tests to understand how Alzheimer's develops. The goal is to find better ways to diagnose and …

This study looks at whether diabetes or blood sugar problems can worsen thinking and memory issues in people with myotonic dystrophy type 1. Researchers will use MRI brain scans and thinking tests over 4 years to track changes. The goal is to understand why some patients have mor…

This study looks at whether adults aged 65 and older with memory concerns can collect a small blood sample at home to check for Alzheimer's disease risk. Participants will use a simple device to draw blood, mail it to a lab, and get results from a doctor over video. The goal is t…

This study looks at whether the immune system mistakenly makes antibodies that attack the body's own nerves and muscles in people with multiple sclerosis, myasthenia gravis, and similar conditions. Researchers will collect blood samples (and sometimes cheek swabs) from 120 adults…

This study enrolls 500 adults with a sleep condition called REM sleep behavior disorder (RBD), which often leads to Parkinson's disease or related brain disorders. Researchers will track symptoms like thinking, movement, and smell to develop a rating scale. The goal is to prepare…

This study looks back at the medical records of 150 people diagnosed with Creutzfeldt-Jakob disease (CJD), a rare and fast-moving brain disorder. Researchers will examine symptoms, blood tests, spinal fluid, brain scans, and EEG results to find patterns that could help doctors di…

This study is testing a new way to analyze MRI brain scans, called Cortical Disarray Measurement (CDM), to see if it can help diagnose Alzheimer's disease more accurately. Researchers will follow 400 people with mild memory or thinking problems over time, comparing CDM results wi…

This study tests whether advanced MRI techniques can measure brain changes in people with ALS (Lou Gehrig's disease). Researchers will scan 119 participants three times over 8 months to see if these scans can track the disease and help diagnose it earlier. The goal is to create b…

This study looks at 40 people with early-stage Huntington's disease and healthy volunteers to see how well two types of brain scans can detect changes over 2 years. Participants get PET and MRI scans plus clinical exams at the start and after 2 years. The goal is to find better w…

This study looks at how swallowing difficulties in people with multiple sclerosis (MS) relate to their nutrition and muscle function. Researchers will assess 34 ambulatory MS patients using questionnaires and physical tests. The goal is to better understand these connections to i…

This study checks whether a French version of a scale called PLSFRS works well for people with primary lateral sclerosis (PLS), a rare nerve disease. Researchers will ask 80 patients to fill out the questionnaire during routine check-ups every 3 to 6 months. The goal is to see if…

This study follows 302 adults with multiple sclerosis in France who are starting the drug ofatumumab as part of their normal care. Researchers will measure how patients' quality of life changes after 12 months using a special questionnaire. The goal is to understand real-world be…

This study looks at how things like social support, income, and health habits are linked to mental health and brain diseases such as depression, Alzheimer's, and Parkinson's. Researchers will collect surveys, blood samples, and optional brain scans from over 1,300 adults in Europ…

This study was designed to test whether scheduled video calls with a nurse could help family members who make medical decisions for hospitalized older adults with Alzheimer's or similar cognitive issues. The goal was to improve communication and reduce anxiety and depression. How…

This study tested two teaching methods for nursing students: a 360-degree video experience about the brain and multiple sclerosis (MS), and a standard slideshow with the same information. About 50 students from three nursing schools took part. Researchers measured how much they l…

This study is creating a simple test to check if people with Alzheimer's or similar conditions can understand and agree to medical decisions. Researchers will work with 100-150 participants to compare the new test with existing methods and look at brain scans and blood markers. T…

This study explores how non-invasive brain stimulation can help understand and treat agitation in people with Alzheimer's and mixed dementia. Researchers will use transcranial magnetic stimulation (TMS) and electroencephalography (EEG) to study brain activity, and test whether tr…

This study is building an online platform called DBS MatchMaker to connect doctors around the world who treat rare movement disorders with deep brain stimulation (DBS). The goal is to help doctors share knowledge and find the best ways to treat patients. Up to 500 people of all a…

This observational study follows 36 people with neurologic conditions like traumatic brain injury, cerebral palsy, multiple sclerosis, or Alzheimer's who are already receiving intranasal MuSE stem cell or exosome therapy as part of their routine care. Researchers track safety and…

This study is creating a registry of 452 adults with a family history of Alzheimer's or early memory problems. Researchers will track their health, blood markers, and thinking skills over time to see if personalized care plans can help prevent or treat the disease. The goal is to…

This study looks at how age-related sleep changes and sleep apnea might increase the risk of Alzheimer's disease. Researchers will use brain scans and overnight sleep tests in 158 healthy adults aged 55-75 to measure amyloid buildup and sleep patterns over two years. The goal is …

This study aimed to test whether a smartphone app could track multiple sclerosis (MS) symptoms and progression remotely. It planned to enroll adults with MS across different countries to see if digital measurements matched standard clinical tests. However, the study was withdrawn…

This study will examine lymph nodes from 5 people with relapsing-remitting multiple sclerosis who are starting ocrelizumab treatment. The goal is to see how effectively the drug removes B cells from lymph nodes, since these cells are known to be important in MS but are not well s…

This study was designed to test a wearable sensor system that tracks how people walk on different surfaces like grass, pavement, and stairs. It aimed to include healthy volunteers and people with conditions such as Parkinson's disease, dementia, stroke, multiple sclerosis, or low…

This study looks at people with early ALS who still have some unaffected body areas. Researchers want to find the very first signs of the disease spreading. By observing 100 participants over time, they hope to learn how ALS starts and progresses, which could help with earlier di…

This study looks at data from 1 million adults worldwide to see if eating nuts is linked to a lower risk of diseases like diabetes, heart disease, cancer, and dementia. Researchers will combine information from many past studies to get clearer answers. The goal is to understand i…

This study aims to find a combination of markers—from genetics, immune system, and brain scans—that are linked to how severe multiple sclerosis (MS) becomes. Researchers will follow 120 people with MS and their siblings who also have the condition. Participants undergo neurologic…

The ALOHA study is a community-based research project for adults aged 50 and older in the Washington, D.C., Maryland, and Virginia area. Over five years, participants receive annual health assessments—including physical and cognitive tests—and get a personalized 'Health Passport'…

This study looks at what happens when healthy older adults learn their personal five-year risk of developing Alzheimer's dementia. Researchers are giving 450 participants their risk estimates at different times and tracking changes in mood, thinking, and distress. The goal is to …

This study brings together patient registries from 10 countries to analyze data from 700 people with spinal and bulbar muscular atrophy (SBMA). Researchers will look at changes in muscle function, walking ability, and age of symptom onset. The goal is to better understand how the…

This study aims to test a risk assessment screening and a caregiver coaching program to prevent elder abuse in people with dementia. Researchers will compare caregivers who receive the screening and coaching to those who do not, looking at stress, depression, and anxiety. The goa…

This long-term study uses yearly brain scans, genetic tests, and thinking/memory assessments to track changes in nearly 1,800 people with various dementias (like Alzheimer's and vascular dementia) and over 140 healthy older adults. The goal is to better diagnose, monitor, and eve…

This study is analyzing blood samples from 1,799 people with Alzheimer's, dementia, depression, bipolar disorder, schizophrenia, or Parkinson's disease. Researchers want to see if certain substances in the blood can help doctors diagnose and manage these conditions more accuratel…

This study is a registry that collects information from about 2,000 people with mild cognitive impairment or Alzheimer's disease. Researchers will track how the disease progresses and how treatments work in real-world settings. The goal is to better understand Alzheimer's and imp…

This study tests whether a phone app called StudyU can help people with heart failure reach their recommended beta blocker dose. Five adults aged 65 and older with heart failure will use the app to track their medication. The goal is to see if the app is practical and acceptable …

This study compares virtual (telehealth) care to standard in-person visits for 120 adults recently diagnosed with multiple sclerosis. The goal is to see if virtual care can prevent disability progression just as well, while also being more convenient and cost-effective. Participa…

The Brain Health Registry is an online project that collects information about memory, mood, sleep, diet, and exercise from adults over 18. Participants also take simple cognitive tests online. The goal is to build a large database to speed up research into brain diseases like Al…

This study follows 432 adults who were in the ICU after a traumatic injury or burn. Researchers want to see if and why patients develop long-term problems with memory, thinking, and daily function. By tracking cognitive skills and inflammation over time, they hope to uncover link…

This observational study plans to enroll 120,000 people with various chronic diseases like pancreatitis, diabetes, and arthritis. Researchers will collect blood samples and health data to study how genetics and lifestyle affect disease progression. The goal is to find common dise…

This study observes 106 Austrian patients with relapsing multiple sclerosis who are already taking Ofatumumab (Kesimpta). Researchers compare those who started the drug early versus later, tracking disease activity over two years. The goal is to see if early treatment leads to fe…

This study monitors indoor air quality in 500 French schoolchildren's classrooms, measuring pollutants like chemicals, allergens, and microbes. Researchers will track asthma and allergy symptoms using questionnaires and lung function tests. The goal is to understand how combinati…

This study planned to see if using a special blood test (PrecivityAD2) could help doctors diagnose Alzheimer's disease or other dementias more quickly. It was designed for veterans and people in other closed healthcare systems who had memory problems. However, the study was withd…

This study looks at whether using an AI tool to analyze brain MRIs helps doctors spot signs of multiple sclerosis (MS) activity more accurately. About 750 people with MS or early warning signs will be split into two groups: one where doctors use the AI tool, and one where they re…

This study is testing whether rehabilitation that combines physical and mental exercises (called dual-task training) can help people with stroke, multiple sclerosis, Parkinson's disease, or long COVID. Researchers will design and try out different dual-task strategies in small gr…

This study follows 90 people with Multiple System Atrophy (MSA), a rare brain disease, for 12 months. Researchers measure changes in movement, thinking, brain scans, and blood markers to better understand how the disease progresses. The goal is to gather information, not to test …

This study is testing a new, comfortable headset that reads brain signals to help people with ALS type on a virtual keyboard. The goal is to improve the device so it can be used in daily life. Five people with ALS will try the headset, and researchers will measure how easy it is …

This study uses a special brain scan called Tau PET to look at a protein linked to Alzheimer's disease in healthy older African Americans. Researchers want to learn how this protein builds up and relates to memory changes over time. The goal is to better understand early signs of…

This study follows 130 older adults with mild to moderate Alzheimer's for up to 5 years to see if frailty (weakness, slow walking, exhaustion, weight loss, low activity) leads to faster loss of daily living skills. Participants are tested at the start and after one year, with lon…

This study is testing whether simple blood tests can accurately diagnose dementia in everyday clinic settings. Over 3,000 people aged 45 and older with memory problems will give blood samples and answer questionnaires. Researchers will check how reliable and acceptable these bloo…

This study aims to learn more about diseases that affect the brain, such as Parkinson's disease and different types of dementia. Researchers will follow 500 adults with symptoms of these conditions over time, using brain scans and genetic tests to see how the diseases progress. T…

This study follows 600 people with and without chronic kidney disease (CKD) for up to four years to compare how often memory loss, confusion, and daily activity problems occur. Researchers will also look for risk factors that make thinking and memory worse in CKD patients. Partic…

This study involves 400 healthy adults aged 60-85 to test new computerized measures of thinking and daily function. Participants are randomly assigned to take either the new tests or standard tests over one year. The goal is to see if the new tests are better at detecting changes…

This study follows 1,400 people with early-stage Alzheimer's or mild cognitive impairment to understand how the disease affects healthcare costs and daily life over time. Participants are not given any experimental treatment. The goal is to gather information for research purpose…

This study looks at the long-term safety of two multiple sclerosis (MS) medications, Vumerity and Tecfidera, by analyzing data from over 10,000 patients in large MS registries. The goal is to track serious side effects, including infections and cancer, and compare them to other M…

This study is testing whether smartphones and wearable devices can detect early signs of Alzheimer's disease better than traditional questionnaires. Researchers will follow 3,500 people with and without memory problems to see if digital tools can spot subtle changes in daily acti…

This study looks at how well the MSCopilot Flower app works for people with multiple sclerosis. The app includes tests for walking, thinking, hand use, and vision, plus questionnaires about fatigue and anxiety. Researchers want to see if patients can use it easily at home and if …

This study follows 132 people with Parkinson's disease or multiple system atrophy who previously received the gene therapy AB-1005. Researchers will track safety and how well the treatment works over the long term. No new treatments are given; it's purely observational.

This study looks at whether group visits in primary care can help adults aged 70 and older complete advance care planning documents, like living wills. About 516 participants will either join two 2-hour group discussions or receive mailed resources. The goal is to see if the grou…

This study looks at whether special brain scans can detect signs of worsening in people with multiple sclerosis (MS). Researchers will scan 35 patients aged 40-50 who have had MS for at least five years. They are measuring brain cell activity that may signal disease progression. …

This study follows 100 people with multiple sclerosis to see if increased activity of certain brain immune cells (microglia) around lesion edges is linked to faster lesion growth over 10 years. Participants had a special PET scan at the start and will have follow-up MRI scans. Th…

This study planned to use brain scans to measure how a meditation technique called OM affects dopamine and stress markers in people with Parkinson's disease. It was withdrawn before enrolling any participants, so no results are available. The goal was to better understand meditat…

This study follows 35 infants with spinal muscular atrophy (SMA) who are receiving gene therapy or other advanced treatments. Researchers use small wearable motion sensors to measure how well the babies move their arms and legs over two years. The goal is to create a more precise…